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Complexity and Power in Case-Control Association Studies
Jeffrey A. Longmate
City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
A general method is described for estimation of the power and sample size of studies relating a dichotomous
phenotype to multiple interacting loci and environmental covariates. Either a simple case-control design or more
complex stratified sampling may be used. The method can be used to design individual studies, to evaluate the
power of alternative test statistics for complex traits, and to examine general questions of study design through
explicit scenarios. The method is used here to study how the power of association tests is affected by problems of
allelic heterogeneity and to investigate the potential role for collective testing of sets of related candidate genes in
the presence of locus heterogeneity. The results indicate that allele-discovery efforts are crucial and that omnibus
tests or collective testing of alleles can be substantially more powerful than separate testing of individual allelic
variants. Joint testing of multiple candidate loci can also dramatically improve power, despite model misspecification
and inclusion of irrelevant loci, but requires an a priori hypothesis defining the set of loci to investigate.
Introduction
In complex diseases, the genetic component of risk may
be spread across several loci, requiring either sufficient
statistical power to detect the modest contribution of
individual genes or some means of evaluating loci col-
lectively. Risch and Merikangas (1996) considered the
former strategy in the context of a single-locus two-allele
system and concluded that association tests are powerful
enough to detect the modest effects of individual loci in
complex disorders. Slager et al. (2000) found that allelic
heterogeneity greatly reduced power for tests of individ-
ual alleles. A general method of power analysis for com-
plex traits is described here and is used to investigate
the power of a broader class of tests in the face of allelic
heterogeneity and misclassification, as well as the alter-
native strategy of collective testing of multiple loci.
The designs considered here involve unrelated con-
trols, as opposed to the parental controls of the trans-
mission/disequilibrium test (TDT) considered in the ref-
erences above. This is motivated by the continuing
practical importance of the case-control design, as well
as by recent methodological work permitting recogni-
tion and adjustment for potentially confounding pop-
ulation structure (Devlin and Roeder 1999; Pritchard
and Rosenberg 1999; Bacanu et al. 2000; Schork et al.
2001). The flexibility of the unrelated control approach,
which includes case-case designs and studies of thera-
peutic efficacy, calls for a flexible power method.
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The approach to power analysis is based on the use
of exemplary data to calculate noncentrality parameters
for the asymptotic x2 distribution of likelihood-ratio
statistics. This approach has been described in varying
degrees of generality in the statistical literature: in the
context of clinical studies by Greenland (1985), in the
context of log-linear models by O’Brien (1986), and in
the context of generalized linear models by Self et al.
(1992), who also consider the matched case-control de-
sign. Brown et al. (1999) comment that these methods
are not as widespread as their generality would seem to
warrant, due to “insufficient appreciation of the
straightforward nature of the calculations and the dif-
ficulty of formulating reasonable specific alternative hy-
potheses.” In the present paper, the method is extended
to encompass general retrospective sampling, imple-
mented as a set of functions in the S language (Chambers
1998), illustrated on a design problem in genetic epi-
demiology and further used to address general questions
in the design of association studies in the face of com-
plex genetic etiology. Because explicit alternativemodels
are used, the method can accommodate very general
models involving incomplete penetrance, phenocopies,
allelic and locus heterogeneity, and interactions among
genes and between genes and covariables. The emphasis
here is on the general method and its application to
allelic and genetic heterogeneity. Other types of genetic
complexity generate questions about the selection of
cases for allele discovery and association testing that are
best addressed separately.
The Method
The exemplary data method provides a general way of
estimating the power of likelihood-ratio tests in complex
models. The general strategy consists of three steps. First,
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we hypothesize a model, here called “the scenario,” un-
der which we wish to calculate power. This consists of
an assumed joint distribution of genetic and nongenetic
risk factors and the conditional penetrance, given each
configuration of risk factors. We then generate an ex-
emplary data set that represents the expected data under
the sampling design. Finally, we analyze the exemplary
data set exactly as we would analyze the actual data,
calculating any likelihood-ratio test of interest. The re-
sulting likelihood ratio can then be used, as described
below, to calculate the power of the same test when
applied to observations generated under the scenario.
Straightforward extensions permit calculation of sample
sizes or detectable effect sizes.
The Likelihood-Ratio Test
In a simple case-control study, cases and controlsn n1 2
are sampled and compared with regard to the frequency
of genotypes. An alternative approach to analysis, par-
ticularly useful in more complex settings, is to fit a lo-
gistic regression model as if the data had been collected
prospectively, taking advantage of the well-known fact
that all but the intercept term in a logistic regression
model can be consistently estimated from retrospective
data (Breslow and Day 1984; Agresti 1990).
Define for a case and for a control andYp 1 Yp 0
let be the penetrance as a functionpp P(Yp 1FXp x)
of x, a vector encoding genotype and covariable infor-
mation (capitals are used here to denote random vari-
ables). In the general logistic formulation, wemodel pen-
etrance, p, by relating the logit of p to a linear model,
p Tlog p h p x b ,( )1 p
where b is a vector of unknown coefficients to be
estimated.
In the simplest case, where for allxp (x ,x ) x p 11 2 1
individuals, and takes the value 1 or 0 to denote thex2
presence or absence, respectively, of a putative high-risk
genotype. Then , where is the logarithmhp b  x b b1 2 2 2
of the odds ratio and is a constant that fits the modelb1
to the numbers of case and control subjects sampled.
We would then test the hypothesis that . Theb p 02
likelihood-ratio test can be computed by fitting both the
full model and a second, reduced model, in which isb2
constrained to equal zero. The goodness of fit of each
model can be measured by the deviance (see, e.g., Agresti
1990, p. 83), which is commonly reported by logistic
regression software. The difference in deviance between
the two fitted models is the likelihood-ratio statistic,
which can be referred to a central x2 distribution—in
this case, with a single df, because of the elimination of
one parameter.
For slightly more generality, consider a single locus
with two alleles, denoted “ ” and “ .” Let be thea a x1 2 2
number of copies of (allele dose), and let ifa x p 12 3
the individual is heterozygous, and zero otherwise. The
likelihood-ratio test statistic, comparing the three-pa-
rameter model with the single-parameter null-effect
model, would then have 2 df. Use of an alternative pa-
rameterization—for instance, being a binary indicatorx2
for the genotype and being the indicator of thea /a x1 2 3
genotype—would not change the likelihood-ratioa /a2 2
test, because either parameterization permits the full
model to exactly fit the observed penetrance for each
genotype.
With k alleles, there are possible dis-dp k(k 1)/2
tinct genotypes, although rare combinations might be
missing from the data. Models with and without d
indicator variables can be compared, to yield a like-1
lihood-ratio test with df. This will be referred tod 1
as the omnibus test, because it is not focused on any one
set of putative high-risk genotypes. Risch and Merikan-
gas (1996) describe separate testing of each allele in their
proposed program of genomewide association testing,
and Slager et al. (2000) considered the effect of allelic
heterogeneity on similar tests of single alleles. The om-
nibus test provides a test for the entire locus that neither
focuses on a single allele nor ignores the distinctions
between other alleles. The 1-df and 2-df tests of a single
allele and the multiple-df omnibus test are all tests of
the same null hypothesis, but the omnibus test compares
the null model to a general alternative hypothesis that
admits allelic heterogeneity.
By using additional x variables, the general logistic
regression model can accommodate multiple alleles per
locus, multiple loci, nongenetic covariables, and inter-
actions among any or all variables. Multiple likelihood-
ratio statistics can be defined to test hypotheses about
the individual and joint effects of genes, and their in-
teractions with each other and with environmental
factors.
The approach to testing can be summarized as follows:
we fit a logistic model for penetrance, log (p/1 p)p
, partition the parameter as , and use theTx b bp (l,w)
likelihood ratio to test hypotheses of the form ,lp l0
provided the intercept is included among the nuisance
parameters, w.
The Scenario
A scenario can be described by specification of the
joint distribution of risk factors, X, and the conditional
penetrance, , for each x—that is, forP(Yp 1FXp x)
each configuration of risk factors. Consider an example
that arose in the course of determination of the feasibility
of detecting genes that may modify the risk of lung can-
cer caused by tobacco smoke. The CYP2E1 gene of the
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Table 1
Scenario: Joint Risk-Factor Distribution
and Penetrance
CYP2E1 and
Smoking Statusa bP(x) cP(yp 1Fx)
c1/c1:
Never .2176 .0001
Former .2816 .0005
Current .1408 .0010
c1/c2:
Never .1088 .0001
Former .1408 .0004
Current .0704 .0008
c2/c2:
Never .0136 .0001
Former .0176 .0002
Current .0088 .0004
a CYP2E1 and smoking status are en-
coded in the vector x (values not shown).
b is the relative frequency of eachP(x)
combination of risk factors.
c is the penetrance, givenP(yp 1Fx)
the risk factors.
cytochrome P450 family 2 locus was considered a can-
didate for a detoxification effect (Matthias et al. 1998).
The frequency of the potentially protective c2 allele was
expected to be ∼20% in the sampled population. That
population was also to be classified with regard to smok-
ing status, as follows: those subjects who had never
smoked (34%), those who formerly smoked (44%), and
those who currently smoke (22%). Table 1 describes this
example by listing all combinations of genetic (CYP2E1)
and environmental (smoking) risk factors, along with
the relative frequency for each combination in the sam-
pled population, under the assumptions of Hardy-Wein-
berg genotype proportions and independence of geno-
type and smoking status.
The last column gives the penetrance for each com-
bination of risk factors. One can either specify each value
directly or specify parameters in a penetrance model.
The latter is convenient if one is considering many risk
factors with few interactions, so that only main effects
need to be specified. In the scenario given in table 1,
there are two interacting factors, and it is, perhaps, eas-
iest to specify the penetrance values directly. It is as-
sumed that the CYP2E1 genotype is irrelevant to non-
smokers, for whom the penetrance is assumed to be
.0001. For the genotype, the penetrance is assumedc1/c1
to be fivefold larger for former smokers and tenfold
larger for current smokers. The allele is assumed toc2
have no effect in nonsmokers, but, in former or current
smokers, we assume that a single copy protects one in
five individuals and that homozygosity for protectsc2
three in five individuals.
Because all models to be considered will include an
intercept, the baseline penetrance has very little effect
on power if the other penetrance values are specified
relative to baseline. In consideration of multiple scenar-
ios, it makes a difference whether effects are specified in
absolute or relative terms, and the exemplary data
method provides a tool for detailed study of the impact
of phenocopy and locus heterogeneity—for example, on
the marginal effect of a locus and on power.
The key effect sizes in the example are the hypothe-
sized protective effects of the genotypes containing c2
alleles, which were stated in relative terms (one in five
protected and three in five protected). It is possible to
fix the ratio of the genotype effects, creating a family of
models parameterized by a single number that can be
optimized to obtain the desired power. If one chooses
to solve for such an effect-size parameter or even to
report it as a summary, the scenario table provides an
explication of the meaning of the effect-size parameter,
in addition to organizing the calculations. Subsequent
sections, however, make no use of detectable effect
calculations.
Expected Data Configurations
To obtain all the possible data configurations, the nine
distinct risk-factor combinations are each combined
with the two possible disease-status values, as shown in
table 2. The column labeled is either the condi-p(yFx)
tional penetrance or its complement, depending on
whether or .yp 0 yp 1
If prospective sampling were feasible, with genotypes
and covariables fixed by design, the penetrance model
alone would determine the power. In fact, most descrip-
tions of the exemplary data method in the statistical
literature focus on such prospective designs. In a pro-
spective study, the expected relative frequency of each
data configuration is
wp P(y,x)p P(yFx)p(x) ,
where is the relative frequency of configuration xp(x)
in the design and is the penetrance model. In aP(yFx)
retrospective study, we sample cases ( ) and con-yp 1
trols ( ) separately, soyp 0
wp P(xFy)p(y) ,
where denotes the sampling proportion allocated top(y)
cases or controls. We can calculate the conditional prob-
abilities of genotypes (and covariables), via Bayes’ rule,
as
P(yFx)P(x)
P(xFy)p ,P(yFx)P(x)
x
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Table 2
Exemplary Data with Weights
y, CYP2E1,
and
Smoking
Status P(x) P(yFx) P(x,yFs) Stratum w
0:
c1/c1:
Never .2176 .9999 .2177 1 .1088
Former .2816 .9995 .2816 1 .1408
Current .1408 .9990 .1407 1 .0704
c1/c2:
Never .1088 .9999 .1088 1 .0544
Former .1408 .9996 .1408 1 .0704
Current .0704 .9992 .0704 1 .0352
c2/c2:
Never .0136 .9999 .0136 1 .0068
Former .0176 .9998 .0176 1 .0088
Current .0088 .9996 .0088 1 .0044
1:
c1/c1:
Never .2176 .0001 .6400 2 .0960
Former .2816 .0005 .3509 3 .1228
Current .1408 .0010 .3509 3 .1228
c1/c2:
Never .1088 .0001 .3200 2 .0480
Former .1408 .0004 .1404 3 .0491
Current .0704 .0008 .1404 3 .0491
c2/c2:
Never .0136 .0001 .0400 2 .0060
Former .0176 .0002 .0088 3 .0031
Current .0088 .0004 .0088 3 .0031
NOTE.— for cases, 0 for controls. All combinations ofyp 1
case status and risk factors are listed. is as in table 1.P(x)
is the penetrance or its complement. is foundP(yFx) P(x,yFs)
from Bayes’ rule, renormalizing within strata. The strata are
sampled in proportions fixed by design (see text).w is the weight
(i.e., the probability for each data configuration in the sample).
where is the relevant population genotype frequencyP(x)
or, more generally, the joint frequency of genotype and
covariates. So, if we consider a specific penetrance
model, , population genotype frequencies, ,P(yFx) P(x)
and sampling proportions, , the weights, w, providep(y)
the expected fraction of the sample with each data
configuration.
The example is slightly more complex than a case-
control study, in that three strata are defined, to permit
oversampling of subjects who had never smoked, who
were of interest for a separate objective involving passive
exposure to tobacco smoke. Let s be one set in a partition
of the full set of pairs. Then, for each s and each(x,y)
in s, we define , where is the(x,y) wp P(x,yFs)p(s) p(s)
fraction of the total sample devoted to stratum s. We
can obtain by computing for eachP(x,yFs) P(yFx)P(x)
configuration, as above, and simply renormalizing sep-
arately within strata. Note that the column labeled
sums to 1 within each stratum. The weights,P(x,yFs)
labeled w, are obtained by multiplying by theP(x,yFs)
planned stratum proportions, which are 50% controls,
15% nonsmoking cases, and 35% smoking or formerly
smoking cases.
Tests and Sample Size
Once a scenario and retrospective sampling propor-
tions have been specified and the expected data config-
uration has been arrived at, it remains to specify a like-
lihood-ratio test and use the exemplary data to calculate
its power. Let be the log likelihood, eval-ˆˆ ˆl(b)p l(l,w)
uated at the maximum-likelihood estimates. The hy-
pothesis that can be tested by fitting a secondlp l0
model under the constraint (the fitted parameter being
denoted “ ”) and calculating the likelihood ratio testˆw0
statistic
2 ˆ ˆˆG p 2{l(l,w) l(l ,w )} .0 0
Usually . Operationally, we fit models with andl p 00
without the components of x corresponding to l and
calculate the difference in deviance.
The test statistic, , can be referred to its asymptotic2G
x2 distribution, calling significant at level a if2 2G G 1
, where , the -quantile of the cen-2q qp x (r,1 a) (1 a)
tral x2 distribution with r df, r being the number of
parameters fixed by the hypothesis. When the null hy-
pothesis does not hold, the distribution of can be2G
approximated by a noncentral x2 distribution; hence, the
power can be estimated by a noncentral x2 probability
function, , evaluated at the critical value q, df r, andF 2x
noncentrality n—that is,
2P(G 1 q)p F (q,r,n) .2x
The key feature that simplifies the power calculations is
that the noncentrality parameter, n, can be estimated
simply as the planned test statistic, , calculated from2G
the exemplary data.
A second simplifying feature is that the noncentrality
scales with sample size. If we want to consider doubling
both the number of cases and the number of controls,
we can simply double the noncentrality parameter,
without further model fitting. Symbolically, we have
in an obvious notation. Many softwaren(n)p nn(1)
packages permit easy calculation of the likelihood-ratio
statistic using fractional counts. This feature permits
finding the sample size necessary for specified power by
a simple root-finding algorithm, without the need to re-
calculate the noncentrality. There are other approaches
to power calculations, but this approach has the advan-
tage of generalizing easily to more-complex situations
while maintaining good accuracy (O’Brien 1986; Self et
al. 1992).
Table 3 shows the analysis-of-deviance table that re-
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Table 3
Analysis of Deviance for Exemplary Data
Effects df Deviance
Residual
df
Residual
Deviance
NULL 17 1.386
Smoking 2 .021 15 1.365
cyp2 2 .003 13 1.362
Smoking:cyp2 4 .002 9 1.360
NOTE.—Each line summarizes a model with the named
effect, and all effects on lines above. “df” and “Deviance”
are differences in residual df and residual deviance. Devi-
ance values are likelihood-ratio (x) statistics comparing the
models on adjacent lines.
Table 4
Total Sample Size, n, for A Single Low-Risk
Allele and 1, 4, or 8 High-Risk Alleles, in Either
Dominant and Recessive Scenarios
ALLELE
FREQUENCIES
df
n
Low
Risk
High
Risk
Dominant
Scenario
Recessive
Scenario
.60 .40 2 749 964
.60 .1# 4 14 1,197 1,541
.60 .05# 8 44 1,751 2,253
NOTE.—The df for omnibus tests are shown in
the column labeled df. All high-risk genotypes
have a relative risk of 2 (penetrance p 0.1 or
0.2). The significance level is andap 0.0001
power is 80%. It is assumed that all alleles are
known.
sults from fitting four models to the weighted exemplary
data of table 2. Each line represents a model involving
the effects listed on that line, as well as all effects listed
above, beginning with the “NULL” model which con-
sists of an intercept only. This table permits forming
several likelihood-ratio tests. If we compare the model
with CYP2E1 main effect (line 3) to the model with
smoking, but no genetic effects (line 2), the test statistic
is , with 2 df, and the noncentrality is2G p 0.003
. Numerically solving for a .01 level of signifi-0.003n
cance and 80% power, we find that 4,672 subjectswould
be needed. If we sum the CYP2E1 main effect and the
interaction, to obtain a 6-df test statistic comparing the
largest model to the smoking model, then the noncen-
trality is and 3,952 subjects are required for the0.005n
same level and power.With simple case-control sampling
(which involves recomputing the exemplary data), the
required sample sizes are 3,039 and 3,448, respectively,
illustrating both loss of power caused by the oversam-
pling of nonsmoking cases and the fact that the optimal
test statistic depends on the design.
The large sample-size requirement, despite a substan-
tial hypothesized effect and a relaxed level of stringency,
suggested that this particular sampling design should be
abandoned. It is included here because it exercises the
major features of the method.
Computer software for the exemplary data method
was written in the form of a set of functions, in the R
dialect (Ihaka and Gentleman 1996) of the S language
(Chambers 1998), that are available from the author and
at his Web site. These do not constitute a stand-alone
program, but rather the additional components needed
within this particular computing environment. A central
component is a function for converting a scenario spec-
ification, like table 1, into a weighted exemplary data
set, like that in table 2. Native functions are used to
create an analysis-of-deviance table, like table 3, and the
noncentrality (deviance) and df are passed to sample-
size or power functions. Together with some functions
to permit simplified specification of a scenario using
Hardy-Weinberg allele frequencies and standard nota-
tion for specification of a penetrance model, these pro-
vide flexible tools for estimation of sample size in com-
plex settings.
Allelic Heterogeneity
The calculation of sample sizes for specific scenarios can
be used to address broad questions of study design, as
well as plans for specific studies. The effect of allelic
heterogeneity on the power of omnibus test statistics is
considered here, along with the impact of efforts to de-
tect and classify allelic variation. The power of joint tests
of several possibly interacting candidate loci is addressed
in the section Genetic Heterogeneity and Multilocus
Testing, below.
Although these sample sizes are calculated for explicit
penetrance probabilities, rather than from formulae
based on relative risk, the noncentrality and sample size
are quite insensitive to the overall penetrance for con-
stant relative risk. Unless otherwise stated, all sample
sizes are presented for test size , and 80%ap 0.0001
power. As a rough approximation, halving or doubling
the sample sizes yields the numbers required for ap
or . The main conclusions, however, de-80.01 ap 10
pend on ratios of sample sizes, which are insensitive to
test size.
Table 4 illustrates the effect of allelic heterogeneity
on sample size, using as an example a single-locus trait,
when all the alleles are known and none are rare. Sce-
narios with both dominant and recessive modes of in-
heritance are considered, but this is assumed to be un-
known to investigators; hence, a 2-df test is used in the
diallelic case. In the second and third lines, the high-
risk allele is essentially subdivided into four or eight
equally frequent alleles. These subdivisions leave the
noncentrality unchanged, so the increase in sample size
is entirely due to the increasing df. If it could be rea-
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Table 6
Sample Sizes, n, for Detected and Undetected
Allelic Heterogeneity
ALLELE FREQUENCIES
df n
Low
Risk
High Risk
Detected
High Risk
Undetected
.95 .05 … 2 624
.95 .02 .01#3 2 1,720
.95 .02, .01#3 … 14 998
NOTE.—Each of the high-risk alleles is domi-
nant, increasing the risk by a factor of 3 relative
to the common allele. The first line is for a scenario
with only two alleles, or, equivalently, for an op-
timal 2-df contrast. Lines 2 and 3 consider 5 alleles,
but for line 2, only the most common of the four
high-risk alleles is detected, with the other high-
risk alleles misclassified as low-risk. “df” denotes
degrees of freedom.
Table 5
Comparison of Multiple-df and Single-df Tests
ALLELE
FREQUENCIES
OMNIBUS
TEST
n FOR SINGLE-
ALLELE TESTS
df n 1-df Test 2-df Test
2#.5 2 744 684 744
4#.25 9 1,048 2,288 2,561
8#.125 35 1,603 5,493 6,177
NOTE.—Sample sizes, n, are shown for scenarios
with two, four, or eight alleles, half of which are high-
risk alleles. An additive mode of inheritance is assumed,
with penetrance for 0, 1, or 2 high-risk alleles being,
respectively, .001, .002, or .003.
sonably hypothesized that the uncommon alleles are all
putatively high-risk alleles, perhaps on the basis of a
predicted loss of function, they could be pooled for anal-
ysis, recovering the power of the 2-df test.
The strategy of separately testing each allele would
not work well in this setting. In the dominant scenario
of line 2, for example, if one of the four high-risk alleles
were singled out for comparison to all other alleles, the
single-df test of the dominant effect of that one allele
would require 5,891 subjects instead of the 1,197 for
the omnibus test. Despite the necessary increase in df,
the omnibus test is more powerful because the tests of
individual alleles may miss the greater part of the risk
attributable to the locus.
Table 5 illustrates a situation with symmetric high-
risk and low-risk allele frequencies and a codominant
allele-dose mode of inheritance. Sample sizes are given
for 1-df (allele-dose) and 2-df tests of a single high-risk
allele, in addition to the omnibus test. The slight ad-
vantage of the optimal single-df test in the simplest
scenario is quickly obliterated by increasing allelic
heterogeneity.
The problem with tests that compare one allele to all
others is that, in the presence of allelic heterogeneity,
several high-risk alleles are effectively misclassified by
the contrast. The power of the omnibus test is robust
to allelic heterogeneity, but all of the allelic variants need
to be detected if the power is to be fully realized. An
example of the effect of undetected alleles is shown in
table 6. In each scenario, the combined frequency of
high-risk alleles is 5%. The first line gives the sample
size in the absence of allelic heterogeneity or if all high-
risk alleles are regarded as equivalent. A 72% increase
in the sample size is needed to accommodate the df of
the underlying allelic heterogeneity in an omnibus test
(line 3), but failure to detect the three least common
alleles requires an increase of 1275% in the required
sample size (line 2), despite fewer df. Evenwith amodest
number of alleles, there is a large advantage to detecting
the relevant allelic variation.
In contrast to the problem of failing to detect high-
risk alleles, we can consider the effect of detecting and
including both low-risk and high-risk alleles among the
variants tested. Of course, an omnibus test withmultiple
df does not require the alleles to be classified into low-
and high-risk categories, but, if such a classification is
plausible, it could be used to improve power by limiting
df. Table 7 describes a scenario with a common low-
risk allele and eight uncommon alleles, only four of
which elevate the risk (as a dominant effect). The om-
nibus test (44 df) requires 2.6 times the sample size of
the optimal (high vs. low risk) contrast. Both of these
assume that all of the allelic variants are detected, but
the latter makes use of prior knowledge as to which are
high-risk alleles, as well as the dominant mode of in-
heritance. If all uncommon alleles are lumped together
as putative dominant alleles, an intermediate sample size
is required. A substantially higher sample size is nec-
essary if only one of the high risk alleles is detected.
With two high-risk alleles detected, the sample size is
comparable to that of the omnibus test of all alleles.
When the rare-versus-common and the two-high-risk
tests—both, to some degree, misspecified—are com-
pared, it is evident that there is a benefit to discovering
all of the relevant allelic variation, even if that effort
also includes some alleles that do not confer risk. How-
ever, the further improvement with correct classification
as to high-risk or low-risk status illustrates the value of
distinguishing the most important mutations. At one
level, we can attempt to distinguish what Sobell et al.
(1992) call VAPSEs (variations affecting protein se-
quence or expression) from silent allelic variation. At
another level, single-locus substitutions at evolution-
arily conserved sites might be separated from those at
nonconserved sites. The advantage of the rare-versus-
common contrast over the omnibus test in table 7 sug-
gests that the advantages of such a distinction may be
robust to a moderate amount of misclassification.
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Table 7
Sample Size, n, with Undetected High-
Risk Mutations and Detection of
Irrelevant Mutations
Test df n
Comparison of nine alleles 44 455
High risk vs. low risk 1 173
One high risk vs. others 1 888
Two high risk vs. others 1 411
Rare vs. common 1 290
NOTE.—The scenario represents a
dominant model, with one common allele
of frequency 84%, eight uncommon al-
leles at 2% each, four of which (high risk)
elevate risk from .01 to .05, the other four
having no impact on risk.
Table 8
Sample Size, n, for Single-Locus and Joint-Effects Tests of Three
Disease-Related Loci and Three Neutral Loci (D, E, and F)
TEST df
n FOR EXAMPLE
1 2 3 4
A locus 2 1,039 459 717 354
B locus 2 901 716 1,138 572
C locus 2 904 1,456 2,169 1,082
ABCABACBCABC 26 612 457 562 327
ABCABACBC 18 543 405 499 290
ABC 6 399 298 464 231
ABC(D) 8 481 359 559 278
ABC(D)(E) 10 543 405 632 314
ABC(D)(E)(F) 12 596 445 693 345
NOTE.—Example 1: multiplicative loci with dominant alleles; RRp
2. Example 2: multiplicative loci with recessive alleles; RR p 3. Ex-
ample 3: interacting loci; RR p 2 for each pair of loci with high-risk
alleles. Example 4: interacting loci; RRp 2 for each individual high-
risk homozygous locus, with an additional multiplicative RRp 3 for
each pair of homozygous loci. High-risk allele frequencies at loci A,
B, and C are 40%, 30%, and 20%, respectively. AB denotes additive
main effects in a logistic model. ABAB denotes inclusion of an
interaction term. All sample sizes are for tests comparing the specified
model to the null (intercept only) model.
Genetic Heterogeneity and Multilocus Testing
Table 8 gives the sample size for tests of individual loci
and for the joint effect of multiple loci. The four columns
of sample sizes correspond to four distinct scenarios in-
volving dominant or recessive effects, either multipli-
cative (log-additive) or interacting. The first three rows
give the sample sizes for tests of single-locusmain effects,
ignoring the other loci. Rows 4, 5, and 6 give sample
sizes for three different tests of the joint effects of the
three loci. All three tests involve main effects but differ
with regard to the inclusion of interactions in the hy-
pothesis. Regardless of the use of interactions, all three
joint-effects tests require smaller samples than do any of
the single-locus tests. The last three rows show the effects
of including additional candidate genes that are not as-
sociated with disease. Each such neutral locus adds 2 df
to the test statistic, without changing the noncentrality.
In all four scenarios, the overall test of main effects is
more powerful than the tests of any single locus, even
when half of the loci tested are unrelated to disease.
Table 8 serves to illustrate the perhaps obvious fact
that, if multiple loci contribute incrementally to pene-
trance, their collective action will provide a stronger
signal than will their individual effects. What is, per-
haps, less obvious is that the test of joint main effects
can be quite powerful, even if the loci interact strongly,
and that the advantages of collecting loci can persist
even when half of those loci have no effect on disease.
One difficulty with testing the joint effect of several
loci is that rejection of the null hypothesis that none of
the loci is associated with disease does not tell us which
loci are associated with disease. However, such a finding
provides protection of the overall false-positive rate, re-
moving much of the onus of multiple comparisons, and
thus indirectly improving the power for detecting in-
dividual loci. Allison and Schork (1997) proposed a
reformulation of the multiple-comparison problem,
which they described as “moving the goal posts” in a
useful way. Their proposal concerned the level of sig-
nificance regarded as compelling in tests of individual
loci. The testing of joint effects is different in at least
two regards. It can be substantially more powerful than
single-locus tests, as is illustrated in table 8, and it does
not involve shifting objectives. It is simply a direct test
of the global null hypothesis about a specific collection
of loci, and it provides a direct and powerful means of
protecting the overall false-positive rate when a collec-
tion of loci are tested.
Such a test is analogous the Fisher’s use of an omnibus
F-test to protect the false-positive rate when multiple
treatments are compared in a one-way analysis of var-
iance. If there is a genuine scientific hypothesis that a
particular pathway is involved in the genetic etiology
of a disease, then the genes involved in that pathway
collectively form an a priori hypothesis, and a test of
their joint effect is an appropriate level of aggregation
for protection of multiple comparisons. So, even though
the direct implications of joint-effects tests are less spe-
cific that those of single-locus tests, by protecting the
overall false-positive rate for a collection of loci, they
permit the testing of individual loci to proceed at un-
adjusted levels of significance, provided, of course, that
the collection of loci represent a well-motivated a priori
hypothesis.
Discussion
The exemplary-data method provides a way of estimat-
ing power for a very large class of likelihood-ratio tests
in a variety of both prospective and retrospective study
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designs. The method relies on asymptotic distributions,
but the large sample sizes of case-control studies make
this a reasonable area for the exemplary-data approach.
Self et al. (1992) consider the accuracy of the method.
Brown et al. (1999) suggest that, in critical applications,
the method should be augmented by simulation studies.
The availability of the exemplary-data table makes
Monte Carlo sampling particularly simple. One only
needs to generate a vector of counts, or indices, with
probabilities given by the weights.
As an illustration, 500 samples were generated to sim-
ulate the last line of table 7. Each sample had 145 cases
and 145 controls. The nominal P values were calculated
for 500 likelihood-ratio tests, of which 347 were
!.0001. Another 85 were between .0001 and .001; 47
were between .001 and .01, 16 were between .01 and
.05, and 5 were 1.05. The simulated power was ∼70%,
rather than the targeted 80%, although 80% of simu-
lated samples had . The method thus seemsP  .0004
a reasonable approximation, in light of the uncertainties
surrounding the specification of realistic scenarios. The
conclusions of the previous sections are based on rel-
ative, rather than absolute, sample sizes.
Risch and Merikangas (1996) cast the problem of
detecting disease-related genes as a question of obtain-
ing sufficient power to detect the modest contributions
of individual loci in a simple two-allele system. Al-
though allelic heterogeneity does not cause serious prob-
lems for linkage-based gene mapping (Lander and
Schork 1994) it can have a profound impact on the
power of association tests (Slager et al. 2000). The large
loss of power for single-allele tests can be ameliorated
by allele discovery, the use of omnibus tests, and a priori
classification of alleles. For testing the effects of the
modest number of common alleles expected per locus,
the use of one omnibus test per locus, combined with
the recent estimate of !40,000 human genes (Venter et
al. 2001), requires an individual test size of 1.25 #
to maintain a genomewide false-positive rate of610
.05 via Bonferroni adjustment, which is somewhat less
onerous than the considered by Risch and85 # 10
Merikangas (1996).
For loci with numerous uncommon alleles, the de-
tection and classification of mutants is important for
implication of the locus in disease etiology. Of course,
one would like to know the risk associated with indi-
vidual genotypes, but a purely empirical estimate may
be impossible for rare alleles. The implication of the
locus as a whole would seem to offer an important
protection against false positives in multiple compari-
sons, as well as a firmer foundation for interpretations
based on the nature of the variants.
Plausible contrasts or groupings of alleles can be de-
fined from consideration of functional implications of
mutations and, for some genes, by evolutionary con-
servation. Such contrasts do not need to be perfect, and
moderate misclassification can be tolerated. The greater
misclassification problem occurs when a substantial
amount of attributable risk is associated with undis-
covered alleles or when individual alleles are tested in
an automatic fashion despite allelic heterogeneity. The
use of markers, as opposed to genes, entails a possibly
severe misclassification. Although it is possible to dis-
cover associations with markers and even for a marker
to correspond coincidentally to an optimal contrast of
alleles, the correct implication of a gene in disease eti-
ology through an association test usingmarkers requires
a substantial amount of luck, making it a strategy more
suitable to broad screening efforts than to hypothesis-
driven research about specific candidate genes.
As we consider increasing numbers of alleles, there
will come a point when the power of an association test
is less than that of a linkage test. Additional power may
be found in the joint testing of multiple genes or in the
use of linkage studies more powerful than affected sib
pairs. The latter might include studies of more-distant
relatives or the detection of regions shared identically
by descent outside of the known family.
Tests of joint effects of sets of candidate genes may
remain feasible when the relative risk associated with
individual loci is simply too small. The difficulty is of
course that this approach requires an a priori hypothesis
defining the collection of loci. Genes involved in com-
mon pathways might be hypothesized to contribute to
a complex genetic etiology, but the relevant pathways
may be large, and similar phenotypes might result from
variation in proteins that play a key role in rather dis-
tantly related pathways. Linking the joint testing ap-
proach to data-driven methods for generating appro-
priate hypotheses might merit further methodological
development.
Acknowledgments
This research was supported in part by National Institutes
of Health grant CA33572. I thank Ralph O’Brien, for intro-
ducing me to the exemplary-data approach, and Ted Krontiris,
Garry Larson, and William Bennett, for helpful discussions.
Electronic-Database Information
The URL for data in this article is as follows:
Author’s Web site, http://www.infosci.coh.org/jal/ (for func-
tions involved in the exemplary data method)
References
Agresti A (1990) Categorical data analysis. JohnWiley&Sons,
New York
Allison DB, Schork NJ (1997) Selected methodological issues
Longmate: Complexity and Power 1237
in meiotic mapping of obesity genes in humans: issues of
power and efficiency. Behav Genet 27:401–421
Bacanu SA, Devlin B, Roeder K (2000) The power of genomic
control. Am J Hum Genet 66:1933–1944
Breslow NE, Day NE (1984) Statistical methods in cancer re-
search, volume I: the analysis of case-control studies. Oxford
University Press, Oxford
Brown BW, Lovato J, Russell K (1999) Asymptotic power cal-
culations: description, examples and computer code. Stat
Med 18:3137–3151
Chambers JM (1998) Programming with data. Springer Verlag,
New York
Devlin B, Roeder K (1999) Genomic control for association
studies. Biometrics 55:997–1004
Greenland S (1985) Power, sample size and smallest detectable
effect determination for multivariate studies. Stat Med 4:
117–127
Ihaka R, Gentleman R (1996) R: a language for data analysis
and graphics. J Comp Graph Stat 5:299–314
Lander ES, Schork NJ (1994) Genetic dissection of complex
traits. Science 265:2037–2048
Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD,
Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF, Hand P,
Fryer AA, Strange RC (1998) Polymorphism in cytochrome
P450 CYP2D6, CYP1A1, CYP2E1 and glutathione s-trans-
ferase, GSTM1, GSTM3, GSTT1 and susceptibility to to-
bacco-related cancers: studies in upper aerodigestive tract
cancers. Pharmacogenetics 8:91–100
O’Brien RG (1986) Using the SAS system to perform power
analyses for log-linear models. In: Proceedings of the Elev-
enth SAS Users Group International Conference, SAS Insti-
tute, Cary, NC, pp 778–784
Pritchard JK, Rosenberg NA (1999) Use of unlinked genetic
markers to detect population stratification in association
studies. Am J Hum Genet 65:220–228
Risch N, Merikangas K (1996) The future of genetic studies
of complex human diseases. Science 273:1516–1517
Schork NJ, Fallin D, Thiel B, Xu X, Broeckel U, Jacob HJ,
Cohen D (2001) The future of genetic case-control studies.
Adv Genet 42:191–212
Self SG, Mauritsen RH, Ohara J (1992) Power calculations
for likelihood ratio tests in generalized linear models. Bio-
metrics 48:31–39
Slager SL, Huang J, Vieland VJ (2000) Effect of allelic het-
erogeneity on the power of the transmission disequilibrium
test. Genet Epidemiol 18:143–156
Sobell JL, Heston LL, Sommer SS (1992) Delineation of genetic
predisposition to multifactorial disease: a general approach
on the threshold of feasibility. Genomics 12:1–6
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton
GG, Smith HO, et al (2001) The sequence of the human
genome. Science 291:1304–1351
